Physician

Sanjaykumar Jagdishbhai Hapani, M.D

According to 2025 Medicare claims, Sanjaykumar Hapani, M.D (NPI: 1952508533) practices medical oncology in the Oklahoma City, OK market, with the plurality of this provider's patient population coming from Oklahoma, OK. This provider's primary affiliated billing organization is OKLAHOMA CANCER AND BLOOD SPECIALISTS, LLC (NPI: 1831485267; TIN: 20-2001573) and primary practice location at 73120-5049. Hapani is affiliated with the Mercy Health ACO, LLC (ACO ID: A2616), participating under the MSSP model.

Hapani's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 876 traditional Medicare patients, billed 206,596 HCPCS/CPT codes, and received $7,299,621 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 3,787 prescription claims across 424 beneficiaries totaling $18,184,625 in drug costs, led by Xtandi (Enzalutamide). 2023 DME data shows 28 claims. Open Payments data shows 133 records totaling $11,150. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $3,427,957 to $7,299,621. Similarly, Part D prescription costs have moved sharply higher in recent years, from $582,698 to $18,184,625. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $2,359 to $423.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	513	169,049	$3,427,957
2016	554	195,586	$3,870,694
2017	542	159,081	$3,250,426
2018	483	266,009	$5,727,488
2019	543	255,803	$6,057,085
2020	513	250,861	$6,354,622
2021	542	255,329	$7,145,795
2022	608	217,299	$7,731,381
2023	644	269,281	$8,236,883
2024	876	206,596	$7,299,621

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	175	1,421	$582,698
2016	187	1,798	$1,492,163
2017	224	1,798	$1,349,764
2018	180	1,732	$1,538,352
2019	223	1,491	$2,348,975
2020	249	2,175	$5,345,634
2021	276	2,499	$8,590,541
2022	303	2,954	$12,825,563
2023	323	3,086	$14,821,915
2024	424	3,787	$18,184,625

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$1,645
2016	N/R	81	$4,200
2017	N/R	177	$45,418
2018	N/R	237	$83,558
2019	N/R	58	$7,704
2020	N/R	51	$9,962
2021	N/R	51	$5,665
2022	N/R	120	$56,949
2023	N/R	28	$5,453
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	288	289	$163
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	668	2,293	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	136	190	$66
96365	Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less	135	302	$46
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	232	351	$13

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	185	5,535	$2,550,004
Octagam	Immun Globg(Igg)/Malt/Iga Ov50	190	5,089	$2,533,496
Imbruvica	Ibrutinib	139	3,892	$2,193,550
Procrit	Epoetin Alfa	481	13,468	$1,691,136
Cabometyx	Cabozantinib S-Malate	38	1,140	$933,358

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	133	$11,150	SUN PHARMACEUTICAL INDUSTRIES INC.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Sanjaykumar Jagdishbhai Hapani, M.D?

Tedicare shows public-source Medicare data for Sanjaykumar Jagdishbhai Hapani, M.D (NPI 1952508533), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Sanjaykumar Jagdishbhai Hapani, M.D have ACO affiliation data?

Sanjaykumar Jagdishbhai Hapani, M.D is shown with ACO affiliation data for Mercy Health ACO, LLC (MSSP, ACO ID A2616).

What billing organization is linked to Sanjaykumar Jagdishbhai Hapani, M.D?

Sanjaykumar Jagdishbhai Hapani, M.D is linked to OKLAHOMA CANCER AND BLOOD SPECIALISTS, LLC (billing NPI 1831485267) in the available physician profile data.

Does Sanjaykumar Jagdishbhai Hapani, M.D have Open Payments data?

Sanjaykumar Jagdishbhai Hapani, M.D has 133 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.